Elekta and Philips Gain MD Anderson Cancer Center as Collaborator in Research Consortium on MRI-Guided Radiation Therapy
ATLANTA, Jan. 24 – Elekta (NSE: EKTAb) and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) announced today that The University of Texas MD Anderson Cancer Center (Houston, Texas) has signed an agreement to join a research group to advance the development of an innovative image-guided treatment technology for cancer care. The technology merges radiation therapy and magnetic resonance imaging (MRI) technology in a single system. MD Anderson is the second member of the research consortium, which will comprise leading radiation oncology centers and clinicians, and already includes the University Medical Center Utrecht (the Netherlands).
Uniting state-of-the-art MRI with a cutting edge radiation therapy system – thus creating an MRI-guided radiation therapy system – will provide physicians with exceptional images of a patient’s soft tissues and tumor during radiation therapy. This breakthrough innovation also aims to enable clinicians to adapt treatment delivery in real time for the most precise cancer treatments possible.
“The special capabilities of the MRI-guided radiation therapy system – MR-based soft tissue imaging performed simultaneously with treatment delivery – could revolutionize cancer care,” says Jay Hoey, Executive Vice President, Elekta North America. “Patients are the ultimate winners, because MR imaging will help put the therapeutic radiation right on target, with the potential to avoid exposure to normal tissues. My colleagues at Elekta, Philips and University Medical Center Utrecht are thrilled to welcome MD Anderson to the research consortium, which will profit immensely from this center’s high-caliber medical, technological and patient care expertise.”
“MRI is the gold standard modality for imaging soft tissues, and MR imaging of the cancer during radiation therapy could provide the health care team the ability to optimize treatment while reducing toxicity,” says Steven J. Frank, M.D., Associate Professor of Radiation Oncology and Director of Advanced Technologies at MD Anderson. “Our collaborative research will focus on what this combination could mean for patients in the future.”
“The development of a meaningful, yet complex innovation like the MRI-guided radiation therapy system can only be done in partnership with leading healthcare innovators, both from an industrial, as well as a clinical perspective,” says Gene Saragnese, CEO Imaging Systems at Philips Healthcare. “As a leading innovator in cancer care, the University of Texas MD Anderson Cancer Center will bring their unique expertise to help realize the promise of more targeted cancer treatments and transform the way healthcare is delivered today.”
Prior to the establishment of the research consortium, Elekta, Philips and the University Medical Center Utrecht have built and tested a prototype system that integrates a linear accelerator and a 1.5 Tesla MRI system. The success of these efforts has enabled the project to move to the next phase of development and testing by the select group of consortium partners.
Radiation therapy and medical imaging already play an essential role in treatment planning, delivery and after care, and are proven, cost-effective and safe methods for the treatment of individuals with cancer. Radiotherapy is a critical modality for cancer treatment, either as a frontline treatment or used with other modalities, such as chemotherapy. The procedure involves identifying cancerous tissue and irradiating it with high-energy radiation beams in a way that maximizes sparing of healthy tissues near the tumor.
The integrated MRI-guided radiation therapy system is in development and not available for sale.
# # #
For further information, please contact:
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: email@example.com
Time zone: ET: Eastern Time
Steve Klink, Philips Corporate Communications
Tel: +31 20 5977415, email: firstname.lastname@example.org
The above information is such that Elekta shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on January 24, 2013.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
About Royal Philips Electronics
Royal Philips Electronics (NYSE: PHG, AEX: PHI) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2011 sales of EUR 22.6 billion and employs approximately 122,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming, home and portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.